Logo image of IMCC

IM CANNABIS CORP (IMCC) Stock Fundamental Analysis

NASDAQ:IMCC - Nasdaq - CA44969Q4060 - Common Stock - Currency: USD

2.51  +0.09 (+3.72%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IMCC. IMCC was compared to 193 industry peers in the Pharmaceuticals industry. IMCC may be in some trouble as it scores bad on both profitability and health. IMCC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

IMCC had negative earnings in the past year.
In the past year IMCC had a positive cash flow from operations.
In the past 5 years IMCC always reported negative net income.
In the past 5 years IMCC always reported negative operating cash flow.
IMCC Yearly Net Income VS EBIT VS OCF VS FCFIMCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of IMCC (-10.43%) is better than 67.88% of its industry peers.
IMCC has a Return On Equity (-88.04%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -10.43%
ROE -88.04%
ROIC N/A
ROA(3y)-119.26%
ROA(5y)-87.85%
ROE(3y)-367.14%
ROE(5y)-273.77%
ROIC(3y)N/A
ROIC(5y)N/A
IMCC Yearly ROA, ROE, ROICIMCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

IMCC's Gross Margin of 18.58% is in line compared to the rest of the industry. IMCC outperforms 51.81% of its industry peers.
In the last couple of years the Gross Margin of IMCC has grown nicely.
IMCC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y497.26%
GM growth 5YN/A
IMCC Yearly Profit, Operating, Gross MarginsIMCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

IMCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMCC has more shares outstanding than it did 1 year ago.
IMCC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for IMCC is higher compared to a year ago.
IMCC Yearly Shares OutstandingIMCC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
IMCC Yearly Total Debt VS Total AssetsIMCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -7.28, we must say that IMCC is in the distress zone and has some risk of bankruptcy.
IMCC's Altman-Z score of -7.28 is on the low side compared to the rest of the industry. IMCC is outperformed by 64.25% of its industry peers.
The Debt to FCF ratio of IMCC is 4.09, which is a neutral value as it means it would take IMCC, 4.09 years of fcf income to pay off all of its debts.
IMCC has a Debt to FCF ratio of 4.09. This is amongst the best in the industry. IMCC outperforms 86.53% of its industry peers.
IMCC has a Debt/Equity ratio of 2.52. This is a high value indicating a heavy dependency on external financing.
IMCC has a worse Debt to Equity ratio (2.52) than 78.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.52
Debt/FCF 4.09
Altman-Z -7.28
ROIC/WACCN/A
WACC11.84%
IMCC Yearly LT Debt VS Equity VS FCFIMCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

IMCC has a Current Ratio of 0.72. This is a bad value and indicates that IMCC is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of IMCC (0.72) is worse than 89.64% of its industry peers.
IMCC has a Quick Ratio of 0.72. This is a bad value and indicates that IMCC is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of IMCC (0.59) is worse than 88.08% of its industry peers.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.59
IMCC Yearly Current Assets VS Current LiabilitesIMCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for IMCC have decreased strongly by -78.84% in the last year.
IMCC shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.68%.
The Revenue has been growing by 16.64% on average over the past years. This is quite good.
EPS 1Y (TTM)-78.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.54%
Revenue 1Y (TTM)12.68%
Revenue growth 3Y16.64%
Revenue growth 5YN/A
Sales Q2Q%3.62%

3.2 Future

IMCC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.54% yearly.
IMCC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.24% yearly.
EPS Next Y86.24%
EPS Next 2Y36.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year41.23%
Revenue Next 2Y26.24%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IMCC Yearly Revenue VS EstimatesIMCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
IMCC Yearly EPS VS EstimatesIMCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -50 -100

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMCC. In the last year negative earnings were reported.
Also next year IMCC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMCC Price Earnings VS Forward Price EarningsIMCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

99.48% of the companies in the same industry are more expensive than IMCC, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 2.77
EV/EBITDA N/A
IMCC Per share dataIMCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A more expensive valuation may be justified as IMCC's earnings are expected to grow with 36.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.54%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMCC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IM CANNABIS CORP

NASDAQ:IMCC (8/6/2025, 8:00:02 PM)

2.51

+0.09 (+3.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-15 2025-05-15
Earnings (Next)08-12 2025-08-12
Inst Owners3.87%
Inst Owner Change4.17%
Ins Owners53.08%
Ins Owner ChangeN/A
Market Cap7.76M
Analysts82.86
Price TargetN/A
Short Float %0.76%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-17.69%
Min Revenue beat(2)-25.65%
Max Revenue beat(2)-9.73%
Revenue beat(4)1
Avg Revenue beat(4)-9.56%
Min Revenue beat(4)-25.65%
Max Revenue beat(4)9.9%
Revenue beat(8)3
Avg Revenue beat(8)-4.84%
Revenue beat(12)3
Avg Revenue beat(12)-9.88%
Revenue beat(16)5
Avg Revenue beat(16)-5.1%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.2
P/FCF 2.77
P/OCF 2.66
P/B 2.01
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.45
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)0.91
FCFY36.09%
OCF(TTM)0.94
OCFY37.53%
SpS12.78
BVpS1.25
TBVpS-0.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.43%
ROE -88.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.58%
FCFM 7.09%
ROA(3y)-119.26%
ROA(5y)-87.85%
ROE(3y)-367.14%
ROE(5y)-273.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y497.26%
GM growth 5YN/A
F-Score7
Asset Turnover1.21
Health
Industry RankSector Rank
Debt/Equity 2.52
Debt/FCF 4.09
Debt/EBITDA N/A
Cap/Depr 7.98%
Cap/Sales 0.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.72
Quick Ratio 0.59
Altman-Z -7.28
F-Score7
WACC11.84%
ROIC/WACCN/A
Cap/Depr(3y)15.95%
Cap/Depr(5y)83.89%
Cap/Sales(3y)1.45%
Cap/Sales(5y)6.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-78.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.54%
EPS Next Y86.24%
EPS Next 2Y36.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.68%
Revenue growth 3Y16.64%
Revenue growth 5YN/A
Sales Q2Q%3.62%
Revenue Next Year41.23%
Revenue Next 2Y26.24%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y66.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year130.87%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y136.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y143.37%
OCF growth 3YN/A
OCF growth 5YN/A